WallStreetZenWallStreetZen

NASDAQ: RLMD
Relmada Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

RLMD earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$98.8M
Current Profit Margin
0%

RLMD Return on Equity

Current Company
-93.4%
Current Industry
-63.5%
Current Market
188%
RLMD's Return on Equity (-93.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RLMD announces earnings.

RLMD Return on Assets

Current Company
-85.1%
Current Industry
2.9%
RLMD is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RLMD Return on Capital Employed

Current Company
-115.74%
Current Industry
19.5%
RLMD's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RLMD vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RLMD$0.00-$98.79M-$98.79MN/AN/A
RZLT$0.00-$56.28M-$56.83MN/AN/A
CTXR$0.00-$37.41M-$39.33MN/AN/A
DBVT$15.73M-$86.72M-$72.73M-0.69%N/A
RPTX$51.13M-$99.03M-$93.80M+722.89%N/A
View Top Biotech Stocks

RLMD earnings dates

Next earnings date
May 9, 2024

Relmada Therapeutics Earnings & Revenue FAQ

What were RLMD's earnings last quarter?

On Invalid Date, Relmada Therapeutics (NASDAQ: RLMD) reported Q4 2023 earnings per share (EPS) of -$0.83, up 34.13% year over year. Total Relmada Therapeutics earnings for the quarter were -$25.17 million. In the same quarter last year, Relmada Therapeutics's earnings per share (EPS) was -$1.26.

If you're new to stock investing, here's how to buy Relmada Therapeutics stock.

What was RLMD's earnings growth in the past year?

As of Q2 2024, Relmada Therapeutics's earnings has grown year over year. Relmada Therapeutics's earnings in the past year totalled -$98.79 million.

What is RLMD's earnings date?

Relmada Therapeutics's earnings date is Invalid Date. Add RLMD to your watchlist to be reminded of RLMD's next earnings announcement.

What was RLMD's revenue last quarter?

On Invalid Date, Relmada Therapeutics (NASDAQ: RLMD) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Relmada Therapeutics's revenue was $0.00.

What was RLMD's revenue growth in the past year?

As of Q2 2024, Relmada Therapeutics's revenue has grown null year over year. Relmada Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.